This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: Arch Development Corporation, Other. Active years: 2001.
Company Filing History:
1 out of 349 
1 out of 834,411 Years Active: 2001
Title: Hiroto Furuta: Innovator in Diabetes Research
Introduction
Hiroto Furuta is a notable inventor based in Wakayama, Japan. He has made significant contributions to the field of diabetes research, holding 2 patents that focus on critical genetic factors related to the disease. His work has implications for diagnostics and therapeutics in diabetes management.
Latest Patents
Furuta's latest patents include innovations in human Nkx-2.2 polypeptide-encoding nucleotide sequences. This invention features a human Nkx-2.2 polypeptide and nucleotide sequences that encode these polypeptides. Specifically, the polynucleotide is the nucleotide sequence of SEQ ID NO:1. The invention also includes polynucleotide sequences that hybridize under stringent conditions to SEQ ID NO:1. Additionally, it encompasses expression vectors and host cells that comprise polynucleotides encoding a human Nkx-2.2 polypeptide. Furthermore, the invention relates to antibodies that specifically bind to a human Nkx-2.2 polypeptide and methods for producing these polypeptides.
Another significant patent addresses mutations in diabetes susceptibility genes, specifically hepatocyte nuclear factor (HNF) 1 alpha, HNF1 beta, and HNF4 alpha. This invention identifies genes responsible for non-insulin-dependent diabetes mellitus (NIDDM) for use in diagnostics and therapeutics. It demonstrates that the MODY3 locus corresponds to the HNF1 alpha gene, the MODY4 locus to the HNF1 beta gene, and the MODY1 locus to the HNF4 alpha gene. The invention also highlights that analyzing mutations in these genes can serve as a diagnostic tool for diabetes and proposes methods for treating diabetes based on these mutations.
Career Highlights
Throughout his career, Hiroto Furuta has worked with various organizations, contributing to advancements in diabetes research. His experience includes working with Arch Development Corporation, where he collaborated on innovative projects aimed at improving diabetes diagnostics and treatments.
Collaborations
Furuta has collaborated with esteemed colleagues such as Graeme I. Bell and Pamela J. Kaisaki. These partnerships have furthered his research and contributed to the development of his patents.
Conclusion
Hiroto Furuta's contributions to diabetes research through his patents and collaborations highlight his role as an innovator in the